

Date of Deposit: October 29, 2001

Attorney Docket No.: 18242-507

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JAN 30 2002

TECH CENTER 1600/2900

APPLICANTS: Hammond et al.

SERIAL NUMBER: 09/543,188

EXAMINER: N. Davis

FILING DATE: April 5, 2000

ART UNIT: 1642

FOR: Prion-binding Ligands and Methods of Using Same

Commissioner for Patents and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Please amend the application as set forth below and consider the following remarks:

In the Claims:

15. (Amended) The peptide ligand of claim 7, wherein said peptide ligand includes the amino acid sequence $X_1X_2X_3X_4X_5X_6$ (SEQ ID NO:40), provided that

X_1 is L, W, or I;

X_2 is L, Q, or F;

X_3 is I, Y, V, F, or L;

X_4 is W or V;

X_5 is I; and

X_6 is P, A, F, or K.

In the Specification:

Insert the supplemental sequence listing pages 1-10 at the end of the specification.

REMARKS

The specification has been amended in response to the September 28, 2001 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice"). Applicants submit herewith a computer readable form (CFR) copy of the "Sequence Listing," a paper copy of the "Sequence Listing," and a statement that the content of the paper and computer readable copies are the same and include no new matter, in compliance with 37 C.F.R. §§ 1.821-1.825. The specification has been amended to insert the sequence listing.